Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today reported financial results for the first quarter 2017, and provided an update on its corporate and clinical development activities.